Literature DB >> 29781812

PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.

Anusara Daenthanasanmak1, Yongxia Wu1, Supinya Iamsawat1, Hung D Nguyen1, David Bastian1, MengMeng Zhang1, M Hanief Sofi1, Shilpak Chatterjee2, Elizabeth G Hill3, Shikhar Mehrotra2, Andrew S Kraft4, Xue-Zhong Yu1,5.   

Abstract

PIM kinase family members play a crucial role in promoting cell survival and proliferation via phosphorylation of their target substrates. In this study, we investigated the role of the PIM kinases with respect to T cell responses in transplantation and tumor immunity. We found that the PIM-2 isoform negatively regulated T cell responses to alloantigen, in contrast to the PIM-1 and PIM-3 isoforms, which acted as positive regulators. T cells deficient in PIM-2 demonstrated increased T cell differentiation toward Th1 subset, proliferation, and migration to target organs after allogeneic bone marrow transplantation, resulting in dramatically accelerated graft-versus-host disease (GVHD) severity. Restoration of PIM-2 expression markedly attenuated the pathogenicity of PIM-2-deficient T cells to induce GVHD. On the other hand, mice deficient in PIM-2 readily rejected syngeneic tumor, which was primarily dependent on CD8+ T cells. Furthermore, silencing PIM-2 in polyclonal or antigen-specific CD8+ T cells substantially enhanced their antitumor response in adoptive T cell immunotherapy. We conclude that PIM-2 kinase plays a prominent role in suppressing T cell responses, and provide a strong rationale to target PIM-2 for cancer immunotherapy.

Entities:  

Keywords:  Bone marrow transplantation; Cancer immunotherapy; Immunology; Transplantation

Mesh:

Substances:

Year:  2018        PMID: 29781812      PMCID: PMC6025986          DOI: 10.1172/JCI95407

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  66 in total

1.  The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease.

Authors:  Leila J Jackson; Jed A Pheneger; Tracy J Pheneger; Gregg Davis; A Dale Wright; John E Robinson; Shelley Allen; Mark C Munson; Laura L Carter
Journal:  Cell Immunol       Date:  2011-10-25       Impact factor: 4.868

2.  The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells.

Authors:  I Sakai; A S Kraft
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

Review 3.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

4.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Authors:  Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

5.  Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population.

Authors:  Hongmei Li; Bardia Nourbakhsh; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

Review 6.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

7.  Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo.

Authors:  Anusara Daenthanasanmak; Gustavo Salguero; Sylvia Borchers; Constanca Figueiredo; Roland Jacobs; Bala Sai Sundarasetty; Andreas Schneider; Axel Schambach; Britta Eiz-Vesper; Rainer Blasczyk; Eva M Weissinger; Arnold Ganser; Renata Stripecke
Journal:  Vaccine       Date:  2012-06-09       Impact factor: 3.641

8.  IL-17 contributes to CD4-mediated graft-versus-host disease.

Authors:  Lucy W Kappel; Gabrielle L Goldberg; Christopher G King; David Y Suh; Odette M Smith; Cassandra Ligh; Amanda M Holland; Jeremy Grubin; Nicholas M Mark; Chen Liu; Yoichiro Iwakura; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

Review 9.  Targeting the Pim kinases in multiple myeloma.

Authors:  N A Keane; M Reidy; A Natoni; M S Raab; M O'Dwyer
Journal:  Blood Cancer J       Date:  2015-07-17       Impact factor: 11.037

10.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Authors:  H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas
Journal:  Ann Oncol       Date:  2014-06-09       Impact factor: 32.976

View more
  9 in total

1.  Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.

Authors:  Anusara Daenthanasanmak; Supinya Iamsawat; Paramita Chakraborty; Hung D Nguyen; David Bastian; Chen Liu; Shikhar Mehrotra; Xue-Zhong Yu
Journal:  Blood       Date:  2018-12-04       Impact factor: 22.113

Review 2.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer.

Authors:  Xue Han; Chune Ren; Tingting Yang; Pengyun Qiao; Li Wang; Aifang Jiang; Yuhan Meng; Zhijun Liu; Yu Du; Zhenhai Yu
Journal:  Oncogene       Date:  2019-07-29       Impact factor: 9.867

4.  Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors:  Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

5.  Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series.

Authors:  Alberto Zamò; Elena Gerhard-Hartmann; German Ott; Ioannis Anagnostopoulos; David W Scott; Andreas Rosenwald; Hilka Rauert-Wunderlich
Journal:  Virchows Arch       Date:  2022-10-11       Impact factor: 4.535

6.  Feedback Loop Regulation between Pim Kinases and Tax Keeps Human T-Cell Leukemia Virus Type 1 Viral Replication in Check.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  J Virol       Date:  2021-11-24       Impact factor: 6.549

7.  Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.

Authors:  Johannes C Melms; Sreeram Vallabhaneni; Caitlin E Mills; Clarence Yapp; Jia-Yun Chen; Eugenio Morelli; Patricia Waszyk; Sushil Kumar; Derrick Deming; Nienke Moret; Steven Rodriguez; Kartik Subramanian; Meri Rogava; Adam N R Cartwright; Adrienne Luoma; Shaolin Mei; Titus J Brinker; David M Miller; Alexander Spektor; Dirk Schadendorf; Nicolo Riggi; Kai W Wucherpfennig; Peter K Sorger; Benjamin Izar
Journal:  Cancer Res       Date:  2019-12-27       Impact factor: 12.701

8.  Berberine promotes XIAP-mediated cells apoptosis by upregulation of miR-24-3p in acute lymphoblastic leukemia.

Authors:  Jian Liu; Zhiwei Chen; Yunping Cui; Huixia Wei; Zhenjing Zhu; Fengxia Mao; Yingchao Wang; Yufeng Liu
Journal:  Aging (Albany NY)       Date:  2020-02-13       Impact factor: 5.682

9.  Anti-Inflammatory Effects of the Novel PIM Kinase Inhibitor KMU-470 in RAW 264.7 Cells through the TLR4-NF-κB-NLRP3 Pathway.

Authors:  Hye Suk Baek; Hyeon Ji Min; Victor Sukbong Hong; Taeg Kyu Kwon; Jong Wook Park; Jinho Lee; Shin Kim
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.